Download by
Scanning QR Code
No Stock Yet
“Nine is impossible”! The General Administration of Market Supervision issued a reminder on the price and competition order of materials related to the epidemic
Teaser: The joint defense and control mechanism of the State Council will hold a press conference at 3:00 p.m.
The State Drug Administration issued a notice on extending the validity period of the COVID-19 antigen detection reagent registration certificate. The validity period of the registration certificate for COVID-19 antigen detection reagents that have been a
“Reference List of Commonly Used Drugs for Home Treatment of People Infected with COVID-19” released
Changes in Hong Kong stocks | Shiyao Group (1093.HK) opened 3.6% higher to fight the novel coronavirus oral small molecule 3CL protease inhibitor SYH2055 received clinical approval
Glonghui, December 8丨Shiyao Group (1093.HK) opened 3.61% higher at HK$8.89, with a total market capitalization of HK$106 billion. The company announced yesterday that the collectively developed SYH2055 has been approved by the State Drug Administration of the People's Republic of China and can conduct clinical research in China. This product inhibits the cleavage of the virus precursor protein by acting on the main protease of the coronavirus (mPro/3clPro), thereby blocking virus replication and playing an anti-coronavirus role. Preclinical studies have shown that this product is suitable for those containing OmicronBA.4 and BA.5 variants
CSPC Pharmaceutical: the oral small molecule anti-novel coronavirus 3CL protease inhibitor SYH2055 developed by the Group has been approved by the State Drug Administration of the people's Republic of China for clinical research in China.
CSPC Pharmaceutical (01093.HK): anti-novel coronavirus oral small molecule 3CL protease inhibitor SYH2055 is clinically approved
CSPC Pharmaceutical (01093.HK) announced that the SYH2055 ("the product") developed by the Group has been approved by the State Drug Administration of the people's Republic of China to conduct clinical research in China. SYH2055 is an oral small molecule anti-novel coronavirus 3CL protease inhibitor developed for the group with global independent intellectual property rights. It is a global innovative drug for class 1 chemicals in China. This product inhibits the cleavage of virus precursor protein by acting on novel coronavirus main protease (Mpro/3CLpro), and then blocks virus replication and plays the role of anti-novel coronavirus.
The anti-epidemic plate of Hong Kong stocks rose and fell, the clover fell by nearly 9%, CSPC Pharmaceutical rose by more than 6%, CANSINOBIO fell by nearly 5%, Junshi fell by more than 4%, and Shanghai Fosun Pharmaceutical fell nearly 4%.
Hong Kong stock anti-epidemic concept stocks rose, Shandong Xinhua Pharmaceutical shares rose nearly 10%, Chinese traditional Chinese medicine rose more than 2%, CANSINOBIO and others rose, CSPC Pharmaceutical and Golly Pharmaceuticals fell by 0.5%.
Hong Kong pharmaceutical stocks rose by shock, Hua Medicine rose nearly 8%, minimally invasive medical treatment rose more than 4%, Green Leaf Pharmaceutical rose nearly 4%, CSPC Pharmaceutical, Shanghai Fosun Pharmaceutical and so on rose.
Loading...
No Stock Yet